The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial - Carlin, Jesse L.; Polymeropoulos, Christos; Camilleri, Michael; Lembo, Anthony; Fisher, Michaela; Kupersmith, Caleigh; Madonick, Darby; Moszczynski, Paula; Smieszek, Sandra; Xiao, Changfu; Birznieks, Gunther; Polymeropoulos, Mihael H. (Clinical gastroenterology and hepatology, 2024)
Keywords: Administration, Oral; Adolescent; Adult; Aged; Diabetes; Diabetes Complications - drug therapy; Double-Blind Method; Female; Gastroenterology and Hepatology; Gastroparesis; Gastroparesis - drug therapy; GCSI; Humans; Male; Middle Aged; Nausea; Nausea - chemically induced; Nausea - drug therapy; Neurokinin-1 Receptor Antagonists - administration & dosage; Neurokinin-1 Receptor Antagonists - therapeutic use; NK-1; Placebos - administration & dosage; RCT; Treatment Outcome; Vomiting; Young Adult; PGI-C; RCT; FDA; NK-1; ITT; Nausea; ANMS; GCSI; Vomiting; OPBS; NK1R; Diabetes; PK; Gastroparesis; GCSDD; American Neurogastroenterology Motility Society; Overall Patient Benefit Scale; pharmacokinetic; Food and Drug Administration; Gastroparesis Cardinal Symptom Index; Gastroparesis Core Symptom Daily Diary; Gastroparesis Cardinal Symptom Index–Daily Dairy; intention to treat; neurokinin-1 receptor; Patient Global Impression of Change